Large-scale accrual of genetically annotated patient samples remains an essential but logistically daunting necessity for advancing this area of research. Institutional trials yield invaluable data, yet consolidating extensive cohorts with comprehensive molecular annotation capable of powering robust biomarker discovery faces considerable barriers. Preclinical models serve a critical role in validating therapeutic candidates aimed at preventing or treating these transformation events. However, the scarcity of human and murine models faithfully recapitulating squamous transformation curtails progress, impeding translational efforts that are vital to bridging molecular insights with clinical application.

Molecular discrepancies distinguishing de novo tumors from those undergoing histological transformation further complicate therapeutic approaches. Evidence indicates that transformed tumors, whether through NE or squamous routes, often retain broad molecular hallmarks of their antecedent adenocarcinoma state, albeit with enhanced heterogeneity. This molecular complexity challenges the notion that transformed tumors mirror their de novo counterparts, suggesting they may constitute distinct biological entities with differential therapeutic vulnerabilities. For instance, transformed small cell lung cancers (SCLC) have demonstrated a trend toward poorer chemotherapy responsiveness relative to their de novo equivalents, with progression-free survival metrics revealing a subtle yet clinically relevant disadvantage that demands further validation.

A nuanced example arises in the context of epidermal growth factor receptor (EGFR)-mutant lung adenocarcinomas, where NE transformation is associated with a noted loss of EGFR expression. Whether analogous downregulation occurs during squamous transformation, or in tumors harboring oncogenic drivers besides EGFR, remains unresolved. The mechanistic underpinnings governing the fate of such driver oncogenes during histological shifts remain a critical area of investigation, holding the potential to inform the development of adaptive therapeutic regimens tailored to dynamically evolving tumor states.

Intriguingly, the tumor microenvironment (TME) emerges as a pivotal but poorly understood player in histological transformation. In vitro studies, leveraging adenocarcinoma cell lines and organoid platforms, reveal minor upregulation of NE or squamous markers upon molecular manipulation. Yet, the full manifestation of transformation phenotypes predominantly occurs within the intricate in vivo milieu, implicating TME-derived signals as essential co-factors in lineage reprogramming. Clinical specimens undergoing such transitions exhibit repression of immune response pathways, hinting that substantial suppression of anti-tumor immunity might be a prerequisite for successful histological conversion. This immune evasion may be a strategy deployed by tumor cells undergoing epigenetic reprogramming toward a stem-like, plastic state, which is otherwise recognized as highly immunogenic. Understanding how tumor cells orchestrate immune suppression during these transitions could unveil novel immunotherapeutic interventions.

A striking question pertains to the directionality of histological transformation. Is it a unidirectional trajectory from adenocarcinoma to an alternative histologic state, or does plasticity allow for reversibility? Studies in NE SCLC suggest that MAPK pathway induction—counterpart to receptor tyrosine kinase signaling—can trigger cell cycle arrest and senescence, indicating an incompatibility between NE phenotype maintenance and MAPK activation. Such findings imply that re-expression of drivers like EGFR might be difficult to achieve once a NE state is established, posing profound implications for the timing and targeting of therapeutic interventions. Moreover, the recognition of transcriptomic heterogeneity and plasticity within SCLC subtypes, including non-NE states characterized by epithelial-mesenchymal transition (EMT) and Notch pathway activation, underscores the dynamic nature of histological phenotypes and their potential reversibility through epigenomic modulation.

Pharmacologic inhibition of epigenetic modulators such as EZH2 and LSD1, implicated in the extensive chromatin remodeling accompanying histological transformation, has been shown to induce shifts from NE to non-NE phenotypes. Such evidence supports the concept that certain transformed states are malleable and potentially subject to therapeutic reprogramming. However, whether these manipulations can fully restore the original adenocarcinoma phenotype or represent partial phenotype resets remains an open and fascinating avenue for exploration with significant therapeutic ramifications.

The clinical and biological landscape becomes even more complex when considering tumors exhibiting combined histology, such as adenosquamous carcinomas, which constitute a modest but notable fraction of lung cancers. These combined tumors might represent either intermediate transformation states in progress or a stable equilibrium in which cellular components with distinct histologies coexist. This equilibrium could provide selective advantages, potentially through cooperative cellular interactions that bolster oncogenicity and enable tumor progression. Such phenomena parallel observations in other cancer types, highlighting the multifaceted interplay of cellular phenotypes within the tumor ecosystem.

An overarching theme emerging from current studies is the conceptualization of tumor histology not as a fixed classification but as a spectrum reflective of underlying plasticity. Both the cellular origin and the repertoire of oncogenic drivers impinge on the phenotypic manifestations and subset of histological states a tumor can adopt. Nevertheless, selective pressures—including pharmacologic inhibitors targeting specific drivers—may disrupt these constraints, enabling transitions across histological states. This paradigm challenges the clinical reliance on microscopic morphology and immunohistochemical markers for histological subtyping, and emphasizes the necessity of more nuanced molecular diagnostics capable of capturing intermediate and transitioning phenotypes.

Recent proposals have coalesced into an “all-plastic” model of histology, positing an inherent tumor capacity to transit between phenotypic states, dictated by external stimuli such as treatment, hypoxia, and microenvironmental signals unless constrained irrevocably by specific genomic alterations. This framework may explain the presence of tumors exhibiting admixed histology or undifferentiated phenotypes, portraying cancer as a dynamic system of lineage flux rather than a static constellation of distinct entities.

Realizing the full potential of this plasticity model demands innovative methodological advances. Single-cell and spatial transcriptomics, alongside sophisticated lineage tracing techniques, are poised to revolutionize our capacity to dissect intratumoral heterogeneity and transformation directionality at unprecedented resolution. These cutting-edge technologies promise to decode the temporal and spatial choreography of histological transformations and to identify the molecular determinants driving such flexibility.

The clinical implications are profound, as appreciating histological transformation as a plastic, dynamic process compels reconsideration of therapeutic strategies. Treatments must adapt not only to the static genotype or phenotype prevailing at diagnosis but also to the evolving tumor landscape shaped by intrinsic plasticity and extrinsic selective pressures. This necessitates integrated, multidimensional molecular profiling over time and potentially combinatorial therapies targeting multiple pathways and the tumor’s adaptive mechanisms to outmaneuver transformation-driven resistance.

While the challenges are formidable, the ongoing elucidation of lineage plasticity and histological transformation heralds an era wherein precision oncology transcends conventional histopathological boundaries. By embracing tumor histology as a fluid spectrum modulated by genomic, epigenomic, and microenvironmental contexts, future therapeutic paradigms may effectively anticipate and counteract the protean nature of cancer.

In summary, histological transformation exemplifies the complex interplay of molecular, cellular, and microenvironmental factors that govern tumor evolution. Overcoming the barriers to understanding and manipulating this plasticity promises to redefine cancer diagnostics and therapeutics, offering hope for improved outcomes in lung and prostate cancers and beyond.

Subject of Research:
Lineage plasticity and histological transformation in lung and prostate cancers, focusing on molecular mechanisms, tumor microenvironment interactions, and clinical implications of tumor phenotype dynamics.

Article Title:
Lineage plasticity and histological transformation: tumor histology as a spectrum.

Article References:
Li, X., Gardner, E.E., Molina-Pinelo, S. et al. Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Res (2025). https://doi.org/10.1038/s41422-025-01180-x

Image Credits:
AI Generated

Pancreatic ductal adenocarcinoma (PDAC) is notorious for its aggressive course and poor prognosis, with most patients succumbing not to the primary tumor burden but rather to systemic spread. While previous research has characterized the molecular subtypes of PDAC and their variable therapeutic vulnerabilities, spatial context within primary and metastatic lesions remained elusive. By employing state-of-the-art spatial transcriptomics on an unprecedented collection of 55 tumor samples from 13 patients, the study maps cellular states and clonal relationships across various metastatic sites, including liver, lung, and peritoneum.

The researchers leveraged rapid autopsy specimens, a resource that permitted a comprehensive survey of both primary tumors and distant metastatic lesions within the same individual. This approach revealed profound shifts in cancer-cell transcriptomic states as tumors disseminate. Notably, distinct lineage states were found to dominate in organ-specific metastases, with the liver and lung harboring markedly different cellular compositions even within the same patient. Such intra-patient heterogeneity underscores the adaptive plasticity of pancreatic cancer cells as they colonize diverse tissue microenvironments.

Crucially, the study constructed phylogenetic trees derived from inferred copy number variations, shedding light on how tumor clones evolve and spread within a single patient. These trees illustrated diverse evolutionary trajectories, highlighting that clonal dissemination is not unidirectional or uniform but rather patient-specific and multifaceted. The ability to map these clonal architectures in spatial context provides essential insights into metastatic seeding patterns and potential vulnerabilities.

Within each metastatic site, multiple tumor lineage states co-existed rather than one dominant clone sweeping through the tissue. Moreover, simultaneous metastatic foci with distinct lineage profiles were observed within the same organ, challenging the traditional view of metastases as monoclonal. This mosaicism reflects both the evolutionary complexity of PDAC and the dynamic interactions between cancer cells and their microenvironment.

The tumor microenvironment (TME) plays a pivotal role in modulating cancer progression and therapy response. By integrating transcriptomic data with spatial information, Pei et al. identified compelling correlations between cancer cell lineage states and features of the surrounding TME. For example, the aggressive basal-like cancer cells predominantly localized with myofibroblastic cancer-associated fibroblasts (myCAFs) expressing transforming growth factor-beta 1 (TGFB1). This spatial proximity was absent in classical or intermediate cancer cell states, indicating a lineage-specific crosstalk that potentially drives more aggressive biology.

Validation via orthogonal methods—including patient-derived organoids and cross-species analysis in mouse models—strengthened these findings, underscoring their biological relevance and reproducibility. Such cross-validation highlights the translational potential of targeting these lineage-specific tumor-stroma interactions in clinical settings.

Interestingly, basal-like cancer cells associated with myCAFs correlated with an exclusion of plasma cells—key components of humoral immunity—from the tumor milieu. Neighboring cell analyses revealed that CXCR4–CXCL12 chemokine signaling pathways may mediate this immune exclusion, unveiling a new axis of immune evasion in metastatic pancreatic cancer. Targeting this signaling axis could reinvigorate immune infiltration and enhance therapeutic efficacy.

The spatially resolved transcriptomic maps also uncover a rich tapestry of cell states and immune contextures, emphasizing the necessity of considering spatial heterogeneity when designing targeted therapies. Tumor lineage plasticity is not merely a snapshot phenomenon but a dynamic process shaped by microenvironmental cues and evolutionary pressures.

By integratively profiling both the genomic and microenvironmental landscapes at high spatial resolution, this study provides a blueprint for understanding how transcriptional plasticity governs metastatic dissemination and immune interactions in PDAC. These insights hold promise for devising novel combination therapies that disrupt key niche interactions and overcome treatment resistance.

The implications of this work extend beyond pancreatic cancer, as spatial transcriptomics can be applied to other refractory metastatic malignancies where lineage heterogeneity and microenvironmental dynamics remain poorly understood. It heralds a new era in cancer research, where spatial context is harnessed to decode tumor complexity and inform precision medicine.

In sum, the meticulous spatial mapping of transcriptomic states across the metastatic spectrum reveals that pancreatic cancer progression is orchestrated by a choreography of tumor cell plasticity, clonal evolution, and niche-specific microenvironmental adaptations. This multidimensional understanding paves the way for innovative therapeutic strategies aimed at dismantling metastatic reservoirs and improving outcomes in this devastating disease.

Subject of Research: Spatial transcriptomic mapping of lineage plasticity and tumor microenvironmental heterogeneity in metastatic pancreatic cancer.

Article Title: Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer.

Article References:
Pei, G., Min, J., Rajapakshe, K.I. et al. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Nature (2025). https://doi.org/10.1038/s41586-025-08927-x

Image Credits: AI Generated